Wegovy is a new weight loss medication that has been approved by the FDA in June 2021. It is a once-weekly injectable medication that helps people lose weight by reducing appetite and food intake. According to Drug Patent Watch [1], Wegovy is a brand name for semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the effects of the hormone GLP-1, which is naturally produced in the body after eating. GLP-1 helps to regulate blood sugar levels and reduce appetite.

Wegovy is similar to another weight loss medication called Ozempic, which is also a GLP-1 receptor agonist. However, Wegovy is more potent than Ozempic, and it is specifically approved for weight loss [2]. According to a study published in the New England Journal of Medicine [3], people who took Wegovy lost an average of 15% of their body weight over 68 weeks, compared to 2.4% for those who took a placebo. In comparison, people who took Ozempic lost an average of 5% of their body weight over 52 weeks, compared to 1.8% for those who took a placebo [2].

Wegovy and Ozempic both have similar side effects, including nausea, vomiting, and diarrhea. However, these side effects are usually mild and go away after a few days or weeks. Both medications can also increase the risk of thyroid cancer, although this risk is considered to be very low [2].

In conclusion, Wegovy is a new weight loss medication that is more potent than Ozempic and specifically approved for weight loss. It works by reducing appetite and food intake, and it has been shown to be effective in helping people lose weight. However, like all medications, it may have side effects, and it is important to talk to a healthcare provider before starting treatment [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.uchealth.org/today/wegovy-vs-ozempic-the-truth-about-new-weight-loss-drugs/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717485/